Clinical Trial Update: FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ION363 in amyotrophic lateral sclerosis with FUS mutations (FU…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• ION363 (ION363)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING